Control
Jun 27 |
Dexamethasone for COVID-19: real-time meta analysis of 12 studies | |
| Meta analysis using the most serious outcome reported shows 11% [-7‑32%] higher risk, without reaching statistical significance. Control Dexamethasone While overall meta-analysis shows poor results, dexamethasone may reduce ris.. | ||
May 14 |
et al., Infection and Drug Resistance, doi:10.2147/IDR.S499371 | Clinical Characteristics and Mortality Trends Among COVID-19 Patients During the First Four Waves in Ngaliema Clinic, Democratic Republic of the Congo |
| 104% higher mortality (p=0.55). Retrospective 410 hospitalized COVID-19 patients in the Democratic Republic of Congo showing significantly lower mortality with vitamin C treatment. | ||
Nov 26 2024 |
et al., PLOS ONE, doi:10.1371/journal.pone.0313289 | Clinical effects of dexamethasone among patients with sickle cell disease hospitalized with COVID-19: Outcomes from a single academic health system |
| 423% higher ICU admission (p=0.14) and 155% longer hospitalization (p=0.06). Retrospective 30 hospitalized patients with sickle cell disease (SCD) showing increased risk of venous thromboembolism (VTE) with dexamethasone treatment for COVID-19. There were also trends towards increased ICU admission and longer hosp.. | ||
Nov 25 2024 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-024-10216-3 | The impact of dexamethasone on short- and long-term mortality in hospitalized COVID-19 patients: a retrospective study |
| 34% lower mortality (p=0.01). Retrospective 576 hospitalized COVID-19 patients showing lower mortality with dexamethasone treatment. | ||
Oct 22 2024 |
et al., Scientific Reports, doi:10.1038/s41598-024-76871-3 | One-year mortality and associated factors in older hospitalized COVID-19 survivors: a Nationwide Cohort Study in Korea |
| 29% higher mortality (p<0.0001). Retrospective 63,369 hospitalized COVID-19 survivors aged 60 years or older in Korea, showing lower 1-year mortality with macrolides (including azithromycin), higher 1-year mortality with corticosteroids (including dexamethasone and.. | ||
Oct 17 2024 |
et al., The Journal of Clinical Endocrinology & Metabolism, doi:10.1210/clinem/dgae734 | Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study |
| 35% higher mortality (p=0.2) and 46% worse improvement (p=0.02). Retrospective propensity score matched study of 529 hospitalized diabetic COVID-19 patients showing no significant difference in mortality or clinical improvement with dexamethasone treatment. | ||
Oct 16 2024 |
et al., Scientific Reports, doi:10.1038/s41598-024-75926-9 | Corticosteroids for hospitalized patients with severe/critical COVID-19: a retrospective study in Chongqing, China |
| 5% higher mortality (p=0.86). Retrospective 406 hospitalized severe/critical COVID-19 patients in China showing no significant difference in 28-day mortality with corticosteroid treatment (methylprednisolone, dexamethasone, or both). Corticosteroids were associated wi.. | ||
Sep 17 2024 |
et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.23-0710 | Circulation of COVID-19-Related Medicines on Japanese Websites during the COVID-19 Pandemic and Their Quality and Authenticity |
| Investigation of the circulation and quality of COVID-19-related medicines sold online in Japan showing poor-quality ivermectin and dexamethasone. Four dexamethasone samples and two ivermectin samples failed quantitative analysis, and thr.. | ||
Aug 24 2024 |
et al., Journal of Clinical Medicine, doi:10.3390/jcm13175013 | Prevalence and Risk Factors of Headache Associated with COVID-19 |
| 42% lower PASC (p=0.08) and 3% improvement (p=0.9). Retrospective 295 hospitalized COVID-19 patients in Slovakia showing 35% prevalence of headache, of which 41% of patients had persistent headache 12-15 months after infection. Authors' analysis of long COVID headache is only for the subgr.. | ||
Aug 22 2024 |
et al., ERJ Open Research, doi:10.1183/23120541.00474-2024 | 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study |
| Retrospective 1,888 patients hospitalized with COVID-19 in the UK showing no significant difference in health-related quality of life or other patient reported outcomes, physical and mental health outcomes, and organ function one year aft.. | ||
Aug 20 2024 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09654-w | Predictors for cause-specific and timing of deaths in patients with COVID-19: a cohort study in Taiwan |
| 103% higher mortality (p=0.0002). Retrospective 2,196 COVID-19 patients in Taiwan (49% mild cases, 44% moderate, 7% severe) showing significantly higher mortality with dexamethasone. | ||
Aug 9 2024 |
et al., Inflammopharmacology, doi:10.1007/s10787-024-01520-0 | Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infection: a propensity score matching study |
| 23% higher mortality (p=0.03). Retrospective 1,167 severe/critical COVID-19 patients in China showing higher 28-day mortality with higher doses of corticosteroids (>50mg/day prednisone equivalent) compared to usual doses (30-50mg/day). The type of corticosteroid used d.. | ||
Jul 17 2024 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2024.1385833 | Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial |
| 134% higher ventilation (p=0.41), 217% higher ICU admission (p=0.46), 17% higher ARDS (p=0.81), and 3% shorter hospitalization (p=0.88). RCT 126 hospitalized COVID-19 pneumonia patients not requiring oxygen at admission, showing no significant difference in outcomes with dexamethasone treatment. | ||
Apr 17 2023 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2023.8516 | Dexamethasone for Inpatients With COVID-19 in a National Cohort |
| 10% lower mortality (p=0.0002). PSM retrospective 80,699 hospitalized COVID-19 patients showing reduced mortality or discharge to hospice with dexamethasone in patients requiring supplemental oxygen or mechanical ventilation/ECMO, but no significant difference in patien.. | ||
Mar 21 2023 |
et al., Pan African Medical Journal, doi:10.11604/pamj.2023.44.142.37858 | Factors associated with COVID-19 fatality among patients admitted in Mashonaland West Province, Zimbabwe 2020-2022: a secondary data analysis |
| 130% higher mortality (p<0.0001). Retrospective 672 COVID-19 patients in Zimbabwe, showing higher mortality with dexamethasone treatment. | ||
Apr 30 2022 |
et al., ERJ Open Research, doi:10.1183/23120541.00129-2022 | A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study |
| 600% worse recovery (p=0.07). Pilot RCT of 7 outpatients with non-severe COVID-19 suggesting potential harmful effects of dexamethasone treatment. Time to recovery was significantly longer in the dexamethasone group compared to controls (p=0.03). Authors note that sys.. | ||
Apr 30 2021 |
et al., European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.173947 | No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial |
| 7% higher mortality (p=1) and 18% higher ventilation (p=0.78). RCT 50 hospitalized COVID-19 ARDS patients showing no clinical benefit with high-dose dexamethasone. | ||
Mar 8 2021 |
et al., medRxiv, doi:10.1101/2021.03.05.21251351 | A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations |
| Retrospective 324 hospitalized patients in Iran reporting on the use remdesivir, favipiravir, methylprednisolone, dexamethasone, and Interferon β1a and their combinations. There is no control group in this study. | ||
Feb 25 2021 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2021436 | Dexamethasone in Hospitalized Patients with Covid-19 |
| 17% lower mortality (p=0.0007), 21% lower ventilation (p=0.03), and 9% higher hospital discharge (p=0.003). RCT 6,425 hospitalized COVID-19 patients showing lower 28-day mortality with dexamethasone treatment. The benefit was most pronounced in patients who had symptoms for more than 7 days at randomization, suggesting dexamethasone is most eff.. | ||
Oct 6 2020 |
et al., JAMA, doi:10.1001/jama.2020.17021 | Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 |
| 3% lower mortality (p=0.85) and 34% improvement (p=0.07). RCT 299 patients with moderate or severe COVID-19-related ARDS showing increased ventilator-free days with dexamethasone treatment. There was no significant difference in 28-day mortality (56.3% vs 61.5%), ICU-free days, or mechanical ven.. | ||
Dec 31 2012 |
et al., Veterinary Parasitology, doi:10.1016/j.vetpar.2012.07.011 | Dexamethasone treatment interferes with the pharmacokinetics of ivermectin in young cattle |
| Analysis of ivermectin and dexamethasone treatment in cattle, showing that dexamethasone interfered with the pharmacokinetics of ivermectin and reduced the efficacy of ivermectin. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.